Henry Schein (NASDAQ:HSIC) CEO Sells $875,742.00 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 10,785 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $81.20, for a total transaction of $875,742.00. Following the transaction, the chief executive officer directly owned 309,092 shares in the company, valued at approximately $25,098,270.40. The trade was a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Henry Schein Trading Up 1.1%

Shares of NASDAQ:HSIC opened at $82.39 on Monday. The company has a 50 day moving average of $77.85 and a 200-day moving average of $72.20. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The firm has a market cap of $9.45 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.44 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the business earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Institutional Investors Weigh In On Henry Schein

Several institutional investors have recently made changes to their positions in HSIC. MAI Capital Management grew its stake in shares of Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares in the last quarter. CW Advisors LLC lifted its stake in Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after acquiring an additional 163 shares during the last quarter. Truist Financial Corp grew its position in Henry Schein by 3.3% in the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after acquiring an additional 175 shares in the last quarter. Simon Quick Advisors LLC increased its stake in shares of Henry Schein by 5.5% during the 2nd quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after purchasing an additional 182 shares during the last quarter. Finally, Claret Asset Management Corp raised its holdings in shares of Henry Schein by 6.3% during the 2nd quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock valued at $232,000 after purchasing an additional 187 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HSIC. JPMorgan Chase & Co. lifted their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Leerink Partners boosted their target price on shares of Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a report on Tuesday, February 24th. Wells Fargo & Company increased their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Finally, Wall Street Zen raised Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.